BNP Paribas Asset Management
MLYS icon

BNP Paribas Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

BNP Paribas Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4K Sell
831
-6
-0.7% -$165 ﹤0.01% 2020
2026
Q1 		$22.7K Buy
+837
New +$24.5K ﹤0.01% 1996

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BNP Paribas Asset Management's MLYS Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Mineralys Therapeutics (MLYS) stake by 0.72% in Q2 2026, selling an estimated $165 and leaving 831 shares worth $22.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2020.

BNP Paribas Asset Management first reported a position in MLYS in Q1 2026 and has held it in 2 quarters since. The position peaked at $22.7K in Q1 2026. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • BNP Paribas Asset Management held 831 shares of Mineralys Therapeutics worth $22.4K as of Q2 2026.
  • BNP Paribas Asset Management sold 6 Mineralys Therapeutics shares in Q2 2026, an estimated $165.
  • Mineralys Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2020 holding.
  • BNP Paribas Asset Management first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • BNP Paribas Asset Management's Mineralys Therapeutics position peaked at $22.7K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.